Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu
  • quotes

  • charts

  • technicals

  • company

Aequus Pharmaceuticals Inc (AQSZF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1155 +20.09%
on 11/06/17
0.1444 -3.95%
on 10/18/17
-0.0213 (-13.31%)
since 10/17/17
3-Month
0.1150 +20.61%
on 09/18/17
0.1719 -19.31%
on 10/10/17
-0.0055 (-3.81%)
since 08/17/17
52-Week
0.1150 +20.61%
on 09/18/17
0.3491 -60.27%
on 03/02/17
-0.0603 (-30.30%)
since 11/17/16

Most Recent Stories

More News
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

Continues to build patent portfolio and strengthen protection for antipsychotic transdermal program following completion of proof of concept clinical trials

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

Continues to build patent portfolio and strengthen protection for antipsychotic transdermal program following completion of proof of concept clinical trials

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

VANCOUVER, BC--(Marketwired - September 07, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

VANCOUVER, BC--(Marketwired - September 07, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
Aequus Provides Second Quarter 2017 Operational Highlights

VANCOUVER, BC--(Marketwired - August 29, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
Aequus Provides Second Quarter 2017 Operational Highlights

VANCOUVER, BC--(Marketwired - August 29, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
EHVVF : 0.1100 (+10.00%)
Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
EHVVF : 0.1100 (+10.00%)
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - August 24, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
CORI : 11.43 (+6.92%)
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - August 24, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.175 (unch)
AQSZF : 0.1387 (-0.36%)
CORI : 11.43 (+6.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 0.1390
1st Resistance Point 0.1388
Last Price 0.1387
1st Support Level 0.1385
2nd Support Level 0.1384

See More

52-Week High 0.3491
Fibonacci 61.8% 0.2597
Fibonacci 50% 0.2321
Fibonacci 38.2% 0.2044
Last Price 0.1387
52-Week Low 0.1150

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart